Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model

Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be effective in patients with brain metastases. However, direct comparative studies of the pharmacokinetics and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Jianlong, Li, Min, Zhong, Wen, Hu, Chengping, Gu, Qihua, Xie, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716766/
https://www.ncbi.nlm.nih.gov/pubmed/29228726
http://dx.doi.org/10.18632/oncotarget.21936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716766/
https://www.ncbi.nlm.nih.gov/pubmed/29228726
http://dx.doi.org/10.18632/oncotarget.21936

Ejemplares similares